TrialClinical breast cancer2011

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.

Ayca Gucalp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.